ASX:OSL

OncoSil Medical Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume2.17 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive OSL News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoSil Medical and its competitors with MarketBeat's FREE daily newsletter.


About OncoSil Medical

OncoSil Medical Limited, a medical device company, focuses on the development of localized treatments for pancreatic and liver cancer in Australia. Its lead product is OncoSil, a brachytherapy device that implants a pre-determined dose of beta radiation directly into cancerous tissue for the treatment of cancer. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in June 2013. OncoSil Medical Limited is headquartered in North Sydney, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.52 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











OncoSil Medical (ASX:OSL) Frequently Asked Questions

What stocks does MarketBeat like better than OncoSil Medical?

Wall Street analysts have given OncoSil Medical a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OncoSil Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is OncoSil Medical's next earnings date?

OncoSil Medical is scheduled to release its next quarterly earnings announcement on Tuesday, August 17th 2021.
View our earnings forecast for OncoSil Medical
.

Who are OncoSil Medical's key executives?

OncoSil Medical's management team includes the following people:
  • Mr. Karl David Pechmann, CFO & Company Sec.
  • Mr. Nigel Lange, CEO, MD & Pres of EMEA
  • Mr. Michael Warrener, Global Sales & Marketing Director
  • Dr. David Charles James, Global Head of Manufacturing Operations
  • Mr. Charles Rowland, Pres of US Operations (Age 70)
  • Dr. Ralph Peters, Chief Medical Officer
  • Mr. David Turner, Head of Medical Affairs

Who are some of OncoSil Medical's key competitors?

What other stocks do shareholders of OncoSil Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSil Medical investors own include Champion Iron (CIA), Blackmores (BKL), APA Group (APA), WiseTech Global (WTC), Twitter (TWTR), Qube (QUB), The Procter & Gamble (PG) and Charter Hall Social Infrastructure REIT (CQE).

What is OncoSil Medical's stock symbol?

OncoSil Medical trades on the ASX under the ticker symbol "OSL."

How much money does OncoSil Medical make?

OncoSil Medical has a market capitalization of $0.00 and generates $2.22 million in revenue each year.

What is OncoSil Medical's official website?

The official website for OncoSil Medical is www.oncosil.com.au.

How can I contact OncoSil Medical?

The company can be reached via phone at 61 2 9223 3344.


This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.